In medical terms, MBD most commonly stands for metabolic bone disease, a group of conditions that weaken bones by disrupting the minerals and processes that keep them strong. The abbreviation can also refer to metastatic bone disease (cancer that has spread to the bones) or, in older medical literature, minimal brain dysfunction (an outdated term for what is now called ADHD). Which meaning applies depends entirely on the clinical context, but metabolic bone disease is by far the most frequent usage.
Metabolic Bone Disease
Metabolic bone disease is not a single condition. It is an umbrella term for any disorder that interferes with your body’s ability to build, maintain, or remodel bone tissue. These disorders typically involve imbalances in calcium, phosphorus, vitamin D, or the hormones that regulate them. The result is bone that is too thin, too soft, or structurally abnormal.
Osteoporosis is the most common form, affecting roughly 200 million people worldwide. It causes a gradual loss of bone mineral density, making bones fragile and far more likely to fracture from minor falls or even routine stress. Osteopenia is a milder version of the same process, where bone density is lower than normal but has not yet reached the osteoporosis threshold.
Other conditions grouped under MBD include:
- Osteomalacia (called rickets in children): bones become soft due to insufficient calcium or phosphorus
- Paget’s disease: bones grow abnormally large and weak, breaking more easily
- Hyperparathyroidism: overactive parathyroid glands pull too much calcium from bone
- Osteogenesis imperfecta: a genetic condition that produces extremely brittle bones
- Cushing syndrome: excess cortisol accelerates bone loss
Symptoms of Metabolic Bone Disease
Many forms of MBD develop silently. Osteoporosis in particular often produces no symptoms at all until a bone breaks. When symptoms do appear, they tend to include persistent bone or joint pain, loss of height over time, a curved or stooped posture, and fractures that happen with surprisingly little force. In osteomalacia, you may notice widespread aching in the bones, especially the hips, legs, and lower back, along with muscle weakness that makes it harder to stand up or climb stairs.
Because these signs overlap with normal aging or other conditions, MBD is frequently diagnosed only after a fracture or an incidental finding on imaging.
How MBD Is Diagnosed
A bone mineral density scan (often called a DEXA scan) is the standard tool for measuring how dense your bones are. The result is reported as a T-score, which compares your bone density to that of a healthy young adult. A T-score of negative 1 or higher is considered healthy. Between negative 1 and negative 2.5 indicates osteopenia. A score of negative 2.5 or lower points to osteoporosis.
Blood tests add another layer of information. Alkaline phosphatase, or ALP, is an enzyme that rises when bone is being broken down or rebuilt abnormally. If ALP is elevated and liver function tests come back normal, the source is likely a bone disorder such as Paget’s disease. Doctors also check calcium, phosphorus, vitamin D, and parathyroid hormone levels to pinpoint which metabolic process has gone wrong.
CKD-MBD: The Kidney Connection
A specific and increasingly recognized form of MBD occurs in people with chronic kidney disease. Called CKD-MBD (chronic kidney disease-mineral and bone disorder), it develops because failing kidneys can no longer filter phosphorus properly or produce enough active vitamin D. Phosphorus builds up in the blood while calcium drops. The parathyroid glands respond by releasing more and more parathyroid hormone, which pulls calcium out of bone to compensate. Over time, this cycle weakens the skeleton and can cause calcium to deposit in blood vessels and soft tissues instead.
Both low and high calcium levels increase the risk of serious complications in kidney disease, which makes managing CKD-MBD a balancing act of controlling phosphorus intake, supplementing vitamin D, and monitoring hormone levels closely.
Treatment for Metabolic Bone Disease
Treatment depends on which type of MBD is involved, but a few strategies apply broadly. Adequate vitamin D is a cornerstone for nearly every form, including osteoporosis, rickets, and hyperparathyroidism. Without enough vitamin D, your body cannot absorb calcium efficiently no matter how much you consume.
Bisphosphonates have been the dominant class of medication for decades. They slow the breakdown of bone and are used across osteoporosis, Paget’s disease, cancer-related bone loss, and even rare conditions like osteogenesis imperfecta. Newer medications work differently. Some stimulate new bone formation rather than simply slowing loss, offering an option for people with severe osteoporosis or those who haven’t responded to other treatments.
Weight-bearing exercise, fall prevention, and ensuring adequate calcium and protein intake are practical steps that support bone health regardless of the specific diagnosis.
Metastatic Bone Disease
When MBD refers to metastatic bone disease, it means cancer that originated in another organ has spread to the bones. This is not bone cancer in the traditional sense. The cancer cells in the bone are still the same type as the original tumor. Prostate cancer carries the highest risk of spreading to bone, with estimates ranging from 18% to 29% of cases. Lung, breast, kidney, and thyroid cancers are also common sources.
Bone metastases typically cause deep, persistent pain that worsens over time and may not respond well to over-the-counter pain relievers. They can weaken bone enough to cause fractures and may also disrupt normal calcium levels in the blood. Treatment focuses on controlling pain, preventing fractures, and treating the underlying cancer.
Minimal Brain Dysfunction: An Outdated Term
In older medical records and literature from the 1960s and 1970s, MBD stood for minimal brain dysfunction, a broad label applied to children with hyperactivity, attention problems, and subtle motor coordination issues. The term was introduced at a 1966 conference and combined what researchers then understood as “brain damage” with a mixed set of learning and perceptual difficulties.
By the late 1970s, research using attention-based tests shifted the focus away from the idea of brain damage and toward attention as the core feature. In 1980, the diagnosis was formally renamed Attention Deficit Disorder (ADD) in the third edition of the Diagnostic and Statistical Manual of Mental Disorders. It was renamed again in 1987 to Attention-Deficit/Hyperactivity Disorder (ADHD), the term still in use today. You may occasionally encounter MBD in this context in older records, but no modern clinician uses it.